Pregnancy success is strongly dependent on the quantitative and qualitative expression profile of placenta-specific genes. Placenta-expressed genes contribute to the regulation of several metabolic-, endocrine-, hormonal-, and immunity-related processes and enhance maternal-fetal communication during human embryonic development ([@B1]). Genomic imprinting is an epigenetic process resulting in monoallelic expression of certain genes in a parent-of-origin-dependent manner ([@B2]). Several genes required for implantation are transcribed only from the alleles inherited from the father ([@B3]). It has been suggested that increased epigenetic variability in placenta has evolved in response to its role in mediating the conflicting demands of the mother and fetus ([@B4]). In eutherian mammals, the phenomenon of genomic imprinting has been attributed a significant role in affecting the evolution and development of placenta and its function in the control of nutritional resources to the fetus ([@B5]).

One of the essential guardians of embryo implantation and the maintenance of early pregnancy is a placenta-specific hormone human chorionic gonadotropin (HCG) ([@B6]). Critically low levels of HCG during the first trimester and low transcription of *CGB* genes represent a sign of either maternal susceptibility to miscarriage, chromosomal anomalies of the fetus, ectopic pregnancy, or failure of *in vitro* fertilization ([@B7],[@B8]). HCG is composed of an α-subunit shared with other glycoprotein hormones and a specific β-subunit coded by a set of primate-specific duplicated *CGB* genes exhibiting up to 99% sequence identity ([@B9],[@B10]). The four *HCG*β-coding genes (*CGB8*, *CGB5*, *CGB*, *CGB7*) together with the ancestral LHβ (*LHB*) and the HCGβ noncoding genes *CGB1* and *CGB2* map to a joint gene cluster at chromosome 19q13.33 (Fig. 1A[](#F1){ref-type="fig"}).

The HCGβ-coding *CGB* genes have several common features with previously described imprinted placenta-specific genes ([@B11]). The *LHB/CGB* region is characterized by high G+C content (≥55 *vs.* 41% human genome average); high repeat-content; and the abundance of CpG islands, which are likely targets of DNA methylation ([@B9]). Despite the nearly identical sequences, a seminal study has reported significant differences in the DNA methylation patterns of the individual *HCG*β genes in human term placenta and tumor cell lines ([@B12]). It has been suggested that the accumulation of repeats in eutherian imprinted gene clusters is coincident with, and may have been a potential driving force in, the development of mammalian genomic imprinting ([@B13]). Also, consistent with the observation that the imprinted genes tend to cluster in the genome ([@B14]), an imprinted paternally expressed gene 3 (*PEG3*; 19q13.4) has been identified in the vicinity of the *LHB/CGB* region ([@B15]).

From the four *HCG* β coding loci the chorionic gonadotropin-β5 (*CGB5*) and the chorionic gonadotropin-β8 (*CGB8*) genes were used as a model because they contribute together 62--82% of the total pool of *HCG*β transcripts ([@B7],[@B16]). This study aimed the following: 1) to determine the parental origin of *CGB5* and *CGB8* transcripts in placentas from cases of uncomplicated and recurrently miscarried pregnancies using single-nucleotide polymorphism (SNP) positions previously described in detail ([@B9]); 2) to define the DNA methylation patterns of *CGB5* promoter in trophoblastic tissues and blood leukocytes; and 3) to explore the role of potential aberrant methylation of *CGB5* promoter in susceptibility to recurrent miscarriage.

The data revealed the significance of biparental expression of *CGB8* and *CGB5* to guarantee an uncomplicated outcome of human pregnancy, identified the correlation between maternally expressed *CGB5* and hemimethylation of the corresponding promoter, and suggested that methylation allelic polymorphism (MAP) or gain of paternal imprinting in *CGB5* may be associated with susceptibility to recurrent miscarriage.

Subjects and Methods
====================

Experimental subjects
---------------------

The study was approved by the Ethics Review Committee of Human Research of the University of Tartu, Estonia (permissions no. 117/9, 16.06.2003 and 126/14, 26.04.2004). A written informed consent to participate in the study was obtained from every family. The study group was recruited at the Women's Clinic of Tartu University Hospital (2003--2005), and all subjects were of white European ancestry and living in Estonia. The study group comprised 23 mother-offspring duos and nine mother-father-offspring trios. At the recruitment, parental peripheral blood samples and placenta material (representing the offspring's genome) for the extraction of genomic DNA and mRNA were collected for each family. Placental samples were obtained from females who underwent the following: 1) elective therapeutic abortion during the first trimester of pregnancy (5--13 wk of gestational age, n = 10); 2) normal delivery at term resulting from uncomplicated pregnancy (39--42 wk of gestational age, n = 14); and 3) cervical dilatation and uterine curettage because of recurrent (patients had three or more spontaneous abortions before the case) incomplete or missed abortion (7--18 wk of gestational age, n = 8). Collected tissue samples were snap frozen in liquid nitrogen and stored at −80 C or placed immediately into RNAlater solution (Ambion Inc., Austin, TX) and kept at −20 C until genomic DNA and RNA isolation, respectively. Parental blood samples for DNA isolation were collected on the day of delivery, abortion, or surgery and frozen at −20 C in EDTA.

Identification of genetically informative cases by resequencing of *CGB5* and *CGB8* in parental-offspring materials
--------------------------------------------------------------------------------------------------------------------

Genomic DNA was extracted from the parental peripheral blood using a protocol based on the salting-out method and from trophoblast tissues (representing the offspring's genome) with the genomic DNA purification kit (Fermentas Life Sciences, Vilnius, Lithuania). Long-range amplification (Fig. 1B[](#F1){ref-type="fig"}) and resequencing (Fig. 1C[](#F1){ref-type="fig"}) across the genomic regions of *CGB5* and *CGB8* was performed as described previously ([@B9],[@B17]). For resequencing the 5′ untranslated region of *CGB5* and *CGB8*, additional primers were designed using Primer3 software (<http://frodo.wi.mit.edu/cgi-bin/primer3_www.cgi>), taking into account polymorphic positions (SNPs) in identified genes ([@B9]) and testing the uniqueness of a primer sequence by BLAST (<http://www.ncbi.nlm.nih.gov/BLAST/>). All PCR and resequencing primers are listed in Supplemental Table 1, published on The Endocrine Society's Journals Online web site at <http://jcem.endojournals.org>.

The obtained sequences were resolved on either ABI 3730 X1 or ABI 3730 XL DNA analyzer (Applied Biosystems, Foster City, CA). The carrier status of SNP alleles in the *CGB5* (rs710899; ss105107003; rs12610392) and the *CGB8* (rs34212754; rs13345685; rs35930240; Fig. 2A[](#F2){ref-type="fig"}) genes ([@B9]) was determined using sequence analysis software PolyPhred (version 6.02; <http://www.phrap.org/phredphrapconsed.html>). All genotypes were confirmed manually to ultimately identify genetically informative cases for the parental origin of *CGB5* and *CGB8* alleles in placental tissues (Fig. 1D[](#F1){ref-type="fig"}).

RT-PCR and detection of gene specific transcripts
-------------------------------------------------

Total RNA was extracted from 90 to 1000 mg of homogenized placental tissue using TRIzol reagent (Invitrogen, Carlsbad, CA) and purified with a NucleoSpin II isolation kit (Machery-Nagel, Düren, Germany) according to the manufacturer's protocols. One microgram of total RNA was reverse transcribed to cDNA using a first-strand cDNA synthesis kit and oligo(dT)~18~ primer (Fermentas) as instructed by the manufacturer. Due to the high-sequence homology in the coding regions of *HCG*β-coding genes, the cDNAs of *CGB5*, *CGB*, and *CGB8* were coamplified from 2 μl of cDNA using a combination of joint primers (CGB5F/CGB8F/CGB8R; Supplemental Table 1) and 1 U of recombinant polymerase (Hot Start *Taq*; AppliChem, Darmstadt, Germany) in 25 μl reaction mixture following the published protocol ([@B7]). *CGB8* cDNA sequences were discriminated from *CGB5* and *CGB* (uncut RT-PCR products, 791 bp) using a *CGB8* sequence-specific restriction with *Dra*I enzyme (Fermentas Life Sciences) resulting in 327-bp (including marker SNPs) and 464-bp restriction fragments (Fig. 2[](#F2){ref-type="fig"}, B, and C) ([@B18]). cDNA sequences of *CGB5* (targeted in this study) and *CGB* (not targeted) were separated based on clonal sequencing and subsequent sequence alignment (ClustalW; <http://www.ebi.ac.uk/clustalw/>), facilitating the identification *CGB5*-specific nucleotide positions as described ([@B9]). Biallelic expression of *CGB5* and *CGB8* in genetically informative placental samples was defined in case the sequenced cDNA clones represented transcripts from both parental alleles. Screening of clones was halted at the identification of at least one cDNA clone per parental allele. Monoallelic expression of maternally inherited allele was defined when no paternal transcripts were present in 20 or more sequenced cDNA clones.

Methylation-sensitive amplification (MS)-PCR of the genomic fragment across *CGB5* promoter region
--------------------------------------------------------------------------------------------------

Bisulfite modification of 1 μg of genomic DNA was performed using the EpiTect bisulfite kit (QIAGEN, Valencia, CA) according to the manufacturer instructions. The bisulfite-treated DNA samples were subjected to two rounds of PCR amplification of the *CGB5* promoter region with the primer pairs specific to either methylated or unmethylated DNA sequences (Supplemental Table 1). To enhance specificity, alternative forward primers (Met_BS_Nest_F, Unmet_BS_Nest_F) were combined with the reverse primers in the nested PCR. The PCR reaction mixture (as described in Ref. [@B7]) contained either 100 ng of bisulfite-converted DNA or 1 μl of the MS-PCR product. Amplification was attained by the GeneAmp PCR System 2700 (Applied Biosystems) thermal cycling for one cycle at 95 C for 3 min to denature and then 30 cycles at 95 C for 20 sec to denature and for 20 sec to anneal and 72 C for 45 sec to extend. The annealing temperature for UNMET-PCR was 61.2 C; for MET-PCR and UNMET-nested PCR, 63.7 C; and MET-nested PCR, 66 C. A final extension step was performed at 72 C for 10 min.

Cloning and sequencing of RT-PCR and MS-nested PCR products
-----------------------------------------------------------

Cloning was performed with gel-puried (UltraClean GelSpin DNA purification kit; MoBio Laboratories, Inc., Solano Beach, CA) *CGB5/CGB*- (791 bp) and *CGB8* (327 bp)-specific cDNA fragments amplified by RT-PCR from placental samples (Fig. 2[](#F2){ref-type="fig"}, B and C and Supplemental Table 1), and methylation-specific nested PCR products of *CGB5* promoter (290 bp for UNMET; 281 bp for MET) amplified from bisulfite-treated genomic DNA of blood and placenta (see Fig. 4A[](#F4){ref-type="fig"} and Supplemental Table 1). All inserts were cloned into pCR\*II-TOPO vector (TOPO TA cloning kit; Carlsbad, CA) according to the manufacturer's instructions, and the presence of the insert was confirmed by colony PCR using vector-specific M13F and M13R primers. Plasmid DNA was extracted with a JetQuick plasmid miniprep spin kit (Genomed, Inc., St. Louis, MO), and DNA concentrations were measured using NanoDrop ND-1000 UV-Vis spectrophotometer (NanoDrop Technologies, Inc., Wilmington, DE). Cloned inserts were sequenced using M13F and M13R primers and BigDye Terminator version 3.1 cycle sequencing kit (Applied Biosystems). Obtained sequences of inserts were aligned and compared with reference sequences using multiple alignment tool implemented in ClustalW.

Screening for genomic rearrangements
------------------------------------

Karyotyping of the placental material for the RM10 case was performed during clinical diagnostics procedure for complicated pregnancies in the University of Tartu Clinics (Tartu, Estonia).

Results
=======

Biparental expression of *CGB5* and *CGB8* is required for pregnancy success
----------------------------------------------------------------------------

Parental origin of the alleles of SNPs in the *CGB5* and the *CGB8* loci was addressed in 32 placentas, including eight cases of recurrent miscarriage (RM), 10 cases of elective termination of pregnancy (ETP) during the first trimester, and 14 cases of normal uncomplicated delivery at term (NP). The markers for the parent-of-origin assignment involved three polymorphic positions in the 5′ untranslated region of both genes (*CGB5*: rs710899, ss105107003, rs12610392; *CGB8*: rs34212754, rs13345685, rs35930240) (Figs. 1[](#F1){ref-type="fig"}, B and C, and 2A[](#F2){ref-type="fig"}). Genetically informative cases (placental tissues) for determination of parental origin of variants were defined as heterozygous in at least one of the three SNPs, whereas at least one parent carried the homozygous genotype at this SNP position (Fig. 1D[](#F1){ref-type="fig"}). From the 32 analyzed cases, nine and 14 placentas were informative for the parental origin of alleles of the studied *CGB5* and *CGB8* SNPs, respectively (Tables 1[](#T1){ref-type="table"} and 2[](#T2){ref-type="table"}). These genetically informative cases were explored for the parental origin of expressed alleles by cloning and sequencing the *CGB5* and *CGB8* mRNA transcripts in placental tissue (Fig. 2[](#F2){ref-type="fig"}, B and C). The majority of placentas revealed biparental expression of *CGB5* and *CGB8* in first- and third-trimester uncomplicated pregnancies as well as RM cases (Tables 1[](#T1){ref-type="table"} and 2[](#T2){ref-type="table"}). Of the sequenced *CGB5* cDNA clones, an equal fraction (50%) represented gene variants inherited from the mother and the father. Among the analyzed *CGB8* transcripts, 46% originated from the maternal and 54% from the paternal gene copy.

Notably, in three analyzed cases, monoallelic expression of the maternal copy of *CGB5* was detected (Table 1[](#T1){ref-type="table"}). These cases represent placenta samples from two recurrent miscarriages (RM9, RM10) and one very early first-trimester electively terminated pregnancy (ETP26; gestational age 4 wk). Despite limited statistical power due to small sample size, there was a trend toward an association between RM and monoallelic *CGB5* expression (Fischer's exact test: *P* = 0.23, all nine samples; *P* = 0.11, ETP26 was excluded as an outlier of very early gestational age).

Uniparentally expressed *CGB5* is accompanied by hemimethylated promoter CpGs
-----------------------------------------------------------------------------

One scenario for the monoallelic expression is transcriptional inactivation of one allele by methylation of CpGs located in gene promoter ([@B2]). This is a common mechanism in imprinted genes, whereby loci are expressed in a parent-of-origin manner. The degree of *CGB5* promoter methylation in placental tissue was determined in the three cases characterized by the transcription of only maternally derived allele in comparison with term placentas exhibiting biparentally expressed *CGB5* (Table 1[](#T1){ref-type="table"}). The MS-PCR of bisulfite-modified DNA revealed the hemimethylated status of gene promoter in all the three placental samples with uniparentally expressed *CGB5* (RM9, RM10, ETP26; Fig. 3[](#F3){ref-type="fig"}). In contrast, term placenta samples (NP44, NP11) were characterized by unmethylated promoter region, whereas all parental DNAs extracted from blood showed almost complete methylation of *CGB5* promoter (Fig. 3[](#F3){ref-type="fig"}). This is consistent with the negligible expression of *HCG*β genes in blood leukocytes ([@B17]).

Next, the detailed comparative CpG methylation profile of the 13 CpG sites within the *CGB5* promoter was addressed by clonal sequencing of bisulfite-converted genomic DNA in the three index and two control cases (Fig. 4A[](#F4){ref-type="fig"}). Consistent with MS-PCR experiments, nearly all the *CGB5* promoter CpGs were methylated in blood DNA samples and unmethylated in term placenta, whereas the three placental samples with maternal *CGB5* expression revealed both methylated and unmethylated promoter variants (Fig. 4B[](#F4){ref-type="fig"}). All other cases exhibiting weak amplification of *CGB5* promoter from placental tissues with methylated DNA specific primers or from blood with unmethylated DNA specific primers were confirmed by clonal sequencing to result from unspecific oligonucleotide annealing (data not shown). Only one CpG site (position −156 from mRNA start) occurred as an outlier of the in consort on-off methylation of the analyzed 13 *CGB5* promoter CpGs and maintained relatively high degree of unmethylation in blood DNA as well as within the methylated promoter variant in the placenta of the three index cases. Identification of polymorphic methylation of *CGB5* promoter CpGs in placenta contributes to the limited list of known epipolymorphisms. The MAP in *CGB5* promoter correlates with obtained gene expression data. Biallelic gene expression was observed in the unmethylated cases, whereas monoallelic expression of the maternal allele was accompanied by the hemimethylated placental DNA. Unfortunately, after bisulfite conversion of genomic DNA, the parental origin of methylated and unmethylated *CGB5* alleles was not identifiable. The observed transcription repression may be mediated by the methylation of transcription factor binding sites ([@B2]). For example, the CpG within a functional Sp1 binding-site (−198 from mRNA start) ([@B19]) is fully hemimethylated in all three cases with uniparentally expressed *CGB5* (Fig. 4B[](#F4){ref-type="fig"}).

One case with uniparental placental expression and MAP in *CGB5* has X monosomy
-------------------------------------------------------------------------------

One of the three placentas (RM10) with uniparental expression and MAP in *CGB5* was identified as a case of Turner syndrome (45, X monosomy; Supplemental Fig. 1).

Discussion
==========

We set forward to study the hypothesis that primate-specific *HCG*β-coding genes *CGB5* and *CGB8* may be imprinted. The hypothesis was based on their genomic location near the known imprinted *PEG3* locus within a cluster of duplicated genes enriched with direct and inverted repeats ([@B15]), the essential role of HCG in human implantation regulated by several imprinted genes ([@B20]) and seminal data on the differential methylation of *HCG*β gene copies ([@B12]). For the *CGB8* gene, the study hypothesis was unequivocally rejected as biallelic expression was identified for 14 of 14 genetically informative cases for the parental origin of alleles. These cases included placental material from uncomplicated first- (ETP; n = 3) and third- (NP; n = 8) trimester pregnancies as well as from cases of RM (n = 3) (Table 2[](#T2){ref-type="table"}). However, for the neighboring duplicate gene *CGB5* (Fig. 1A[](#F1){ref-type="fig"}), monoallelic expression of the maternal allele was detected for three of the nine informative cases (33.3%), whereas six placentas (66.7%) showed transcription of *CGB5* from both parental alleles.

Although preferential monoallelic expression can occur also in a non-parent-of-origin pattern ([@B21]), we hypothesized that the uniparental expression of the maternal *CGB5* allele in the two RM and one ETP cases might result from polymorphic epigenetic silencing of the paternal copy. The observed correlation of monoallelic expression and hemimethylation in *CGB5* promoter supported the existence of an epipolymorphism or MAP. MAP has been defined as an on-off type of epigenetic variant resulting from interindividual variations in CpG methylation and contributing to interindividual differences in gene expression and phenotypic variation ([@B22]). When occasional silencing of one allele and monoallelic expression of another allele depends on its parental origin, it may represent a case of polymorphic imprinting ([@B23]). The first reports on polymorphic imprinting of human genes were on *IGF2R* (insulin-like growth factor 2 receptor) in placenta ([@B24]), *WT1* (Wilms' tumor suppressor gene) in placenta, lymphocytes, and fibroblasts ([@B25],[@B26]), *IGF2* (insulin-like growth factor 2) in lymphocytes ([@B27]), and *HTR2A* \[5-hydroxytryptamine (serotonin) receptor 2A\] in adult brain ([@B28]). Recently a large-scale study reported epipolymorphisms in *WNT2* (wingless-type MMTV integration site family member 2), *TUSC3* (tumor suppressor candidate 3), and *EPHB4* (ephrin type B receptor 4), which were methylated in 7--25% of human placenta samples, and their promoter methylation was concordant with mRNA allelic expression. In three informative cases, the *TUSC3* promoter was methylated on the maternal allele, and it was suggested to represent a polymorphically imprinted gene ([@B22]). Unfortunately, in the current study, we were unable to determine the parental origin of the methylated and unmethylated alleles of *CGB5* due to limited number of marker polymorphisms and loss of information about their parental origin in bisulfite-treated DNA. Whether the monoallelic maternal gene expression of *CGB5* associated with the hemimethylation of the promoter represents a true polymorphic gain of imprinting (GOI), or just a MAP, remains to be determined.

Although polymorphic loss of genomic imprinting has been reported to be common in human first-trimester ([@B29]) and term placenta ([@B30]), there are few data on GOI. In our study, two of the three cases with hemimethylated promoter and maternally monoallelically expressed *CGB5* in placenta were cases of RM, and one represented an early (gestational age 4 wk) ETP. Another pregnancy-related complication, the late-onset preeclampsia displayed in placenta significantly (*P* \< 0.05) more frequent methylation of *TUSC3* promoter (GOI: maternal) compared with uncomplicated pregnancies ([@B22]). These findings promote to ask whether methylation and/or GOI in loci sensitive to gene dosage in successful placental function represent a mark for adverse pregnancy outcomes. Consistently, in chorionic villus samples of abortions/stillbirth significantly more abnormal methylation values for the nonimprinted *APC* (adenomatosis polyposis coli tumor suppressor) and the imprinted *PEG3* genes were reported ([@B31]). In fetal muscle samples, methylation abnormalities in multiple genes were observed in 4% of spontaneous abortions and 18% of stillbirths, whereas none of the induced abortions displayed extreme methylation ([@B32]). The phenomenon of polymorphic imprinting in human diseases is not limited to the placenta. In patients with core myopathies, polymorphic epigenetic allele silencing of the maternal allele of *RYR1* (ryanodine receptor 1) was reported in skeletal muscle (six of 11 patients), whereas the studied normal adult skeletal muscle samples displayed only biallelic expression ([@B33]).

Emergence of an epipolymorphism(s) could be due to either a sequence-dependent allele-specific DNA methylation (*cis* effect) ([@B34]) or affected by *trans*-acting factors in genome-wide or locus level. The effect of the local DNA sequence on the *CGB5* promoter methylation is unlikely because there was no correlation between DNA methylation profile and allelic status of neighboring SNPs (Tables 1[](#T1){ref-type="table"} and 2[](#T2){ref-type="table"}). Our study detected hemimethylated CpG (−198 from mRNA start) in *CGB5* promoter coupled with monoallelic gene expression within experimentally defined Sp1 transcription factor binding site ([@B19]) (Fig. 4[](#F4){ref-type="fig"}). This Sp1 site appears to be conserved among all *HCG*β-coding genes (*CGB*, *CGB5*, *CGB7*, *CGB8*) ([@B35]), and mutations of this sequence were shown to cause a dramatic reduction in the promoter's basal activity (83%) ([@B19]). Another interesting observation was the detection of 45, X monosomy in one of the three cases with the hemimethylated *CGB5* promoter. Initiation of X inactivation and parent-of-origin silencing of imprinted genes has evolved in parallel and is mediated by similar molecular mechanisms ([@B36]). In the case of Turner syndrome, this entire process may be disturbed. It has been shown that aneuploidy drives to modified gene expression patterns and cellular physiology ([@B37]). This may be mediated via epigenetic modifications as shown in cancer tissues, in which aneuploidy and changes in DNA methylation patterns occur hand-in-hand ([@B38]). It is also possible that the detected *CGB5* MAP is only a tag for methylation-associated functional alteration of another gene(s) primarily increasing susceptibility to miscarriage.

Aberrant locus-specific methylation has also been related to the effect of antisense transcription ([@B23]). The *LHB/CGB* locus includes two *HCG*β noncoding genes (*CGB1*, *CGB2*) ([@B35]). Most intriguingly, the upstream regions distinct to these genes harbor a novel genes *snaR* (small nuclear factor 90 associated RNA). *SnaR*s encode noncoding RNA substrates for a nuclear factor 90 protein and are transcribed from an antisense strand in testis, placenta, and brain ([@B39]). Whether the transcripts of *HCG*β noncoding or *snaR* genes have any role in modulating the expression of *HCG*β genes (*CGB5*, *CGB8*, *CGB*, *CGB7*) in genomic or mRNA level is unknown.

In summary, we showed that for normal uncomplicated pregnancy biparental expression of major *HCG*β genes appears to be optimal. We discovered *CGB5* as a novel epipolymorphic gene with possible occasional gain of paternal polymorphic imprinting (GOI). Monoallelic expression of *CGB5* and hemimethylation of its promoter were described in the first-trimester placenta in two cases of RM and one case of ETP. Due to delicacy of the recruitment procedure, the limited study sample does not exclude that this observed enrichment of RM cases was a chance finding nor allows to assess whether the detected uniparental expression of one (of four) *HCG*β coding *g*enes had a direct effect on maternal serum HCG. The expression of *CGB* genes and serum HCG levels are dependent on gestational age and course of pregnancy and display high interindividual variation ([@B7],[@B16]).

Aberrant methylation patterns in placenta during early pregnancy may represent random reprogramming defects affecting normal implantation process. Alternatively, MAP in placenta directing to the pregnancy failure may arise as a response to cellular stress caused by, in general, aneuploidy or environmental conditions in placental-maternal interface. It has been suggested imprinting may have evolved to act as a genomic cloaking device of either maternal or paternal allele during critical periods in development when selective abortion is possible ([@B40]). Placental polymorphic GOI may have developed to serve as a flexible tool affecting the quality of implantation process and increasing the probability of miscarriage in unfavorable developmental conditions for the offspring.
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Abbreviations: CGB8, Chorionic gonadotropin-β8; CGB5, chorionic gonadotropin-β5; ETP, elective termination of pregnancy; GOI, gain of imprinting; HCG, human chorionic gonadotropin; LHB, LHβ gene; MAP, methylation allelic polymorphism; MS, methylation-sensitive amplification; NP, normal uncomplicated delivery at term; PEG3, paternally expressed gene 3; RM, recurrent miscarriage; SNP, single-nucleotide polymorphism; TUSC3, tumor suppressor candidate 3; UTR, untranslated region.

![Determination of the parental origin of SNP alleles in *CGB5* and *CGB8* loci in placental genomic DNA. Panel A, Schematic presentation of the human *LHB/CGB* gene cluster at 19q13.33. Panel B, Amplified genomic regions specific to the *CGB5* and *CGB8* loci using a combination of long-range and nested PCR (*connected black arrows*, primers A--F in Supplemental Table 1). Panel C, Sequenced segments in the amplified *CGB5* and *CGB8* loci harboring marker SNPs (*short red bars*, primers I--L in Supplemental Table 1). Panel D, Example of a genetically informative placental tissue for the parental origin of variants: heterozygosity in placenta and homozygosity at least in one of the parents. Chr, Chromosome; kb, kilobase.](zeg0011177760001){#F1}

![Localization of marker SNPs used to identify the parental origin of *CGB5* and *CGB8* transcripts at the genomic (A) and the mRNA (B) sequences (*black vertical arrows*). RT-PCR primers O--Q are given in Supplemental Table 1. C, Separation of *CGB5/CGB* and *CGB8* transcripts by locus-specific restriction of cDNA using *Dra*I restriction enzyme. Clonal sequencing of the uncut cDNA was performed in the informative cases for *CGB5* SNP(s) and the shorter restriction fragment (327 bp) in the informative cases for the *CGB8* SNP(s). EX, Exon; INT, intron.](zeg0011177760002){#F2}

![MS-PCR of the *CGB5* promoter region. High degree of methylation (M) was detected in all analyzed parental blood DNAs, almost complete unmethylation (U) in uncomplicated term placenta samples (NP44, NP11), and hemimethylation in cases of uniparentally expressed *CGB5* (RM10, RM9, ETP26), M, Methylated DNA-specific PCR (563 bp); U, unmethylated DNA-specific PCR (571 bp); NC, negative control.](zeg0011177760003){#F3}

![Fine-scale determination of the methylation status of *CGB5* promoter region in placenta and blood using bisulfite sequencing. A, Localization of analyzed CpG sites (*vertical lines*) in the upstream and transcribed region of *CGB5*. Positions of primers (Supplemental Table 1) for the amplification and clonal sequencing of methylated (V, S) and unmethylated (Z, U) promoter sequence from bisulfite-modified DNA are indicated. One differentially methylated CpG site is located within the Sp1 binding site, critical in the basal *HCG*β expression ([@B19]). B, The methylation status of 13 CpG sites within the analyzed region of the *CGB5* locus in parental blood DNA (almost complete methylation), placental samples from term pregnancies (NP 44, NP11; almost complete unmethylation) and from placentas with monoallelic expression of the maternal *CGB5* allele (RM10, RM9, ETP26; hemimethylation). Four to 10 clones were sequenced per each sample, and the methylation-specific primer combination (UNMET, MET) showed consistent methylation patterns. *Filled circle*, methylated CpG site; *open circle*, unmethylated CpG site. Sp1, Selective promoter factor 1.](zeg0011177760004){#F4}

###### 

Parental origin of *CGB5* mRNA transcripts in the placental tissue of genetically informative cases

  Informative cases   Gestational age[a](#TFN1-1){ref-type="table-fn"}   Genotype of rs710899[b](#TFN1-2){ref-type="table-fn"}   Genotype of ss105107003[b](#TFN1-2){ref-type="table-fn"}   Genotype of rs12610392[b](#TFN1-2){ref-type="table-fn"}   Origin of expressed allele                                                               
  ------------------- -------------------------------------------------- ------------------------------------------------------- ---------------------------------------------------------- --------------------------------------------------------- ---------------------------- -------- ---- ---- ------- -------- -------- ---- --------- -------------------
  RM                                                                                                                                                                                                                                                                                                                                           
   RM4                14 wk + 5 d                                        AA                                                      AA                                                         AA                                                        A                            CC       CC   CC   C       **G**G   **C**G   GC   **G/C**   Maternal/paternal
   RM9                10 wk + 0 d                                        AA                                                      AA                                                         AA                                                        A                            **T**C   CC   CT   **T**   **G**G   GC       GC   **G**     Maternal
   RM10               11 wk + 6 d                                        AA                                                      NA                                                         AA                                                        A                            CC       NA   CC   C       **G**G   NA       GC   **G**     Maternal
  ETP                                                                                                                                                                                                                                                                                                                                          
   ETP26              4 wk + 0 d                                         **A**A                                                  NA                                                         AG                                                        **A**                        CC       NA   CC   C       **G**G   NA       GC   **G**     Maternal
   ETP27              7 wk + 5 d                                         AA                                                      NA                                                         AA                                                        A                            CC       NA   CC   C       **C**C   NA       GC   **C/G**   Maternal/paternal
   ETP30              11 wk + 6 d                                        AA                                                      NA                                                         AA                                                        A                            CC       NA   CC   C       **G**G   NA       GC   **G/C**   Maternal/paternal
  NP                                                                                                                                                                                                                                                                                                                                           
   NP11               40 wk + 6 d                                        **A**A                                                  AG                                                         AG                                                        **A/G**                      CC       CC   CC   C       **G**G   **C**G   GC   **G/C**   Maternal/paternal
   NP44               40 wk + 4 d                                        **A**A                                                  NA                                                         AG                                                        **A/G**                      CC       NA   CC   C       GC       NA       GC   G/C       Maternal/paternal
   NP45               39 wk + 0 d                                        **A**A                                                  NA                                                         AG                                                        **A/G**                      CC       NA   CC   C       **G**G   NA       GC   **G/C**   Maternal/paternal

NA, Not available. 

Gestational age at the collection of placental tissues is shown in weeks and days. 

Genotypes of the mother (M), the father (F), and the offspring (PL) were determined in genomic DNA extracted from peripheral blood (M, F) or from placental tissue (PL). Genetically informative positions are indicated in *bold*. 

Cloned and sequenced placental mRNA transcripts. 

###### 

Parental origin of *CGB8* mRNA transcripts in the placental tissue of genetically informative cases

  Informative cases   Gestational age[a](#TFN2-1){ref-type="table-fn"}   Genotype of rs35930240[b](#TFN2-2){ref-type="table-fn"}   Genotype of rs13345685[b](#TFN2-2){ref-type="table-fn"}   Genotype of rs34212754[b](#TFN2-2){ref-type="table-fn"}   Origin of expressed allele                                                                 
  ------------------- -------------------------------------------------- --------------------------------------------------------- --------------------------------------------------------- --------------------------------------------------------- ---------------------------- -------- -------- ---- --------- -------- ---- ---- --------- -------------------
  RM                                                                                                                                                                                                                                                                                                                                              
   RM1                8 wk + 5 d                                         AA                                                        AA                                                        AA                                                        A                            **A**A   **G**A   GA   **A/G**   CC       CC   CC   C         Maternal/paternal
   RM2                12 wk + 3 d                                        AA                                                        AA                                                        AA                                                        A                            **A**G   **G**G   GA   **A/G**   CC       CC   CC   C         Maternal/paternal
   RM9                10 wk + 0 d                                        **A**A                                                    **T**A                                                    TA                                                        **A/T**                      GG       GA       GG   G         CC       CC   CC   C         Maternal/paternal
  ETP                                                                                                                                                                                                                                                                                                                                             
   ETP12              8 wk + 0 d                                         AA                                                        NA                                                        AA                                                        A                            **G**G   NA       GA   **G/A**   CC       NA   CC   C         Maternal/paternal
   ETP27              7 wk + 5 d                                         AA                                                        NA                                                        AA                                                        A                            **G**G   NA       GA   **G/A**   CC       NA   CC   C         Maternal/paternal
   ETP30              11 wk + 6 d                                        AA                                                        NA                                                        AA                                                        A                            **G**G   NA       GA   **G/A**   CC       NA   CC   C         Maternal/paternal
  NP                                                                                                                                                                                                                                                                                                                                              
   NP9                38 wk + 6 d                                        AA                                                        AA                                                        AA                                                        A                            **G**G   **A**A   GA   **G/A**   CC       CC   CC   C         Maternal/paternal
   NP12               40 wk + 6 d                                        **T**A                                                    **A**A                                                    AT                                                        **T/A**                      GG       GA       GG   G         CC       CC   CC   C         Maternal/paternal
   NP29               40 wk + 6 d                                        AA                                                        AA                                                        AA                                                        A                            **A**G   **G**G   GA   **A/G**   CC       CC   CC   C         Maternal/paternal
   NP36               40 wk + 1 d                                        AA                                                        NA                                                        AA                                                        A                            **G**G   NA       AG   **G/A**   CC       NA   CC   C         Maternal/paternal
   NP37               40 wk + 5 d                                        AA                                                        NA                                                        AA                                                        A                            **G**G   NA       AG   **G/A**   CC       NA   CC   C         Maternal/paternal
   NP44               40 wk + 4 d                                        **A**A                                                    NA                                                        AT                                                        **A/T**                      GA       NA       GA   A/G       CC       NA   CC   C         Maternal/paternal
   NP45               39 wk + 0 d                                        AA                                                        NA                                                        AA                                                        A                            **A**A   NA       GA   **A/G**   **C**C   NA   GC   **C/G**   Maternal/paternal
   NP63               41 wk + 6 d                                        AA                                                        NA                                                        AA                                                        A                            **A**A   NA       GA   **A/G**   CC       NA   CC   C         Maternal/paternal

NA, Not available. 

Gestational age at the collection of placental tissues is shown in weeks and days. 

Genotypes of the mother (M), the father (F), and the offspring (PL) were determined in genomic DNA extracted from peripheral blood (M, F) or from placental tissue (PL). Genetically informative positions are indicated in *bold*. 

Cloned and sequenced placental mRNA transcripts. 
